section name header

Overview

Topic Editor: Sara Millican, MBBS

Review Date: 12/26/2012


Definition

Pediatric pneumonia is a lower respiratory tract infection with consolidation of the alveolar spaces, in a patient less than 18 years of age.

Description

Epidemiology

Incidence/Prevalence

Age

Risk factors:

Etiology

Aged <4 weeks:
Organisms responsible for pneumonia in children aged <4 weeks include
Aged 4 weeks to 3 months:
Most pathogens in this age group are community acquired bacteria. Organisms responsible include
Age 3 months to 8 years:
The most common cause of pneumonia is viruses:
Bacterial causes include:
Age >8 years:
Immunocompromised:
Recent immigrants from developing countries:
Less common:

History & Physical Findings

History

Symptoms

In all age groups:

Respiratory distress Aged >5 years

Physical Findings

In all age groups:
  • Abdominal tenderness (lower lobe pneumonia or due to splinting from cough)
  • Accessory respiratory muscle use (retractions at subcostal, intercostal muscle groups)
  • Cyanosis (with severe pneumonia)
  • Decreased breath sounds (respiratory fatigue or consolidation or reactive airways)
  • Dullness to percussion overlying consolidation
  • Fever
  • Hypoxia
  • Maculopapular rash
  • Nonspecific symptoms of illness e.g. dehydration, oliguria, abdominal distention
  • Rales/Crackles (more common in older age groups)
  • Rhonchi (sounds like snoring or a coarse rattling sound)
  • Tachycardia
  • Tachypnea
  • Wheezing
Aged <6 months:
  • Apnea (especially RSV in premature infants)
  • Grunting
  • Nasal congestion
  • Nasal flaring
  • Staccato cough (chlamydia)
  • Temperature instability (hypothermia/hyperthermia)
  • Wheezing
Aged >5 years:
  • Chills
  • Rigors

Laboratory & Diagnostic Testing/Findings

Blood tests findings

Basic laboratory tests and radiology may not be indicated for simple, uncomplicated pneumonia as it adds a little over careful clinical management of such cases.

  • Complete blood count (CBC) with differential:
    • Suggestive of infective process; patients with a bacterial infection tend to have leukocytosis with left shift; however septic patients may have a leukopenia
    • Patients with B. pertussis generally have a markedly raised white blood cell (WBC) count with a predominance of lymphocyte in early disease
  • Blood culture:
    • Not indicated for uncomplicated pneumonia to be treated in the outpatient setting
    • Recommended for all patients with severe community-acquired pneumonia, however the results are rarely positive and when positive rarely modify empiric therapy
    • Indicated in all patients <1 month age due to the hematogenous origin and spread of organisms in this group
  • Inflammatory markers:
    • Inflammatory markers are useful in septic neonates. Although some recommendations for use of CRP to monitor the course of pneumonia exist; this hasn't been shown to be of any value over competent clinical assessment in most cases
    • If performed; generally CRP is the most appropriate test due to its superior specificity and sensitivity. There is no value to obtaining both a CRP and ESR
    • Note that these markers may have delayed rise in acute illness
  • Serology:
    • Can be used for diagnosis of species such as Chlamydia species, M. pneumoniae, and Legionella (low yield in cultures)
    • Infection may be indicated by a four-fold increase in serum and convalescent titers
Other laboratory test findings
  • Sputum (gram stain and culture)
    • Sputum for gram stain and culture may be obtained in hospitalized patients with suspected bacterial infection. It is of highest value in complex cases such as severe disease, complicating factors (significant recent antibiotic use, cystic fibrosis, immunosuppression)
    • In most cases this test fails to yield a definitive result nor impact empiric therapy
    • Not used in patients <10 years as sputum generally not produced and if so likely to be contaminated by oral flora
  • Rapid urinary antigen tests:
    • Test provides high specificity and sensitivity
    • Recommended in patients with severe disease
  • Polymerase chain reaction (PCR):
    • Noninvasive test which has advantages over bronchoalveolar lavage or lung aspirate. May facilitate a more rapid diagnosis for C. pneumonia or M. pneumoniae
  • Cold agglutinin testing:
    • Serologic test useful to support the diagnosis of M. pneumoniae infection
    • Test has low specificity, and is positive in about 1 in 2 cases of mycoplasma infection
  • Rapid viral diagnostic tests:
    • Nasopharyngeal specimens are recommended for viral isolation
    • More sensitive than culture, and may detect low quantities of viral ribonucleic acid (RNA)

Radiographic findings

  • Chest radiograph:
    • May not be required in uncomplicated cases where history and examination are consistent with pneumonia
    • Chest x-ray is the modality of choice when pneumonia is suspected, but findings are inconsistent and/or complications are suspected
      • The x-ray is abnormal at presentation in ~40% of pneumonia cases
      • The typical pattern is that of alveolar/lobular infiltrates with air bronchograms
      • Diffuse infiltrates are more common with atypical organisms or viruses
      • The x-ray generally cannot differentiate between bacterial and viral pneumonia
  • Computed tomography (CT):
    • Most useful modality for defining extent of complications of pneumonia and/or in severe disease to which antibiotic treatment fails to elicit a response
    • Chest CT can be used to monitor for lung nodules, or cavitation within a lung infiltrate and to evaluate for underlying neoplasm
    • Chest CT is not a first line test due to the radiation dose. It is appropriate in complex, severe, unusual, or prolonged cases

Other diagnostic test findings

  • Bronchoscopy:
    • Bronchoscopic samples of lower respiratory secretions are indicated in patients with complications, persistent hypoxia, or no response to therapy or presence of pulmonary abscess
    • Cultures of endotracheal aspirates or expectorated sputum may be used to assess for drug-resistant or atypical pathogens
  • Thoracentesis:
    • Performed for both diagnostic and therapeutic value in children with parapneumonic effusions

Differential Diagnosis

  • Acute respiratory distress syndrome
  • Afebrile pneumonia syndrome (infant pneumonitis)
  • Agammaglobulinemia
  • Alveolar-capillary dysplasia
  • Alveolar proteinosis
  • Asphyxiating thoracic dystrophy (Jeune syndrome)
  • Aspiration syndromes
  • Asthma
  • Bacteremia
  • Birth trauma
  • Bronchiectasis
  • Bronchiolitis
  • Bronchitis
  • Bronchogenic cyst
  • Chest wall injury or anomaly
  • Chylothorax
  • Chronic granulomatous disease
  • Coccidioidomycosis
  • Combined B-Cell and T-Cell disorders
  • Common variable immunodeficiency
  • Complement deficiency
  • Congenital diaphragmatic hernia
  • Congenital heart disease
  • Congenital pneumonia
  • Congenital stridor
  • Congestive heart failure
  • Croup
  • Cystic adenomatoid malformation
  • Cystic fibrosis
  • Empyema
  • Esophageal atresia w/ or w/o tracheoesophageal fistula
  • Foreign body in airway
  • Gastroesophageal reflux disease
  • Goodpasture's syndrome
  • Hemosiderosis
  • Hemothorax
  • Histoplasmosis
  • HIV infection
  • Hypersensitivity pneumonitis
  • IgA and IgG subclass deficiencies
  • Inborn errors of metabolism
  • Inhalation injury
  • Lung tumor
  • Metabolic acidosis
  • Neonatal bowel obstruction
  • Neural tube defects
  • Persistent newborn pulmonary hypertension
  • Pertussis
  • Pleural effusion
  • Pneumothorax
  • Pulmonary atelectasis
  • Pulmonary atresia
  • Pulmonary edema
  • Pulmonary embolism
  • Pulmonary hemorrhage
  • Pulmonary hypoplasia
  • Pulmonary sequestration
  • Sarcoidosis
  • Sepsis
  • Smoke inhalation
  • Wegener's granulomatosis

Treatment/Medications

General treatment items

  • The age of the patient and severity of disease and other issues (hydration, hypoxia, need for IV therapy) determine the location (hospital versus home) and nature of treatment required
  • Neonates are almost exclusively treated as inpatients
  • Initial treatment:
    • Identify and provide therapy for respiratory distress, hypoxemia or hypercarbia
      • Pulse oximetry should be performed and oxygen should be administered to achieve saturations above 94-95%
      • Monitor oxygen saturation by pulse oximeter continuously for children with increased work of breathing or significant distress
      • Effectiveness of pulmonary ventilation can be assessed via a blood gas to evaluate the PCO2 (venous is adequate)
      • Children who are severely ill i.e. unable to maintain adequate oxygenation, inadequate ventilation or who have a decreased level of consciousness, should undergo intubation for clinical respiratory failure
      • Children with septic shock or severe sepsis may also benefit from intubation and ventilation
    • IV hydration, correction of dehydration and resuscitation (0.9% NS or lactated ringers in 10 - 20 mL/kg boluses) is required if the patient is in shock or hypovolemic. In sepsis, multiple boluses and vasopressors are commonly requiredA bedside glucose should be obtained in all critically ill infants and toddlers. If hypoglycemic is present, administer dextrose 10% solution at 5 mL/kg intravenous (IV) bolus for neonates or dextrose 25% at 2 mL/kg IV bolus for toddlers
    • Critically ill children requiring ventilation should be promptly administered appropriate antibiotics
      • Delay may be associated with longer duration of ventilation, ICU stay and total length of hospitalization
    • Children with reactive airway disease need specific treatment with bronchodilators (e.g. albuterol)
    • Perform thoracocentesis if a significant pleural effusion is present surrounding the pneumonia, for both diagnostic and therapeutic purposes
  • Empiric antibiotic treatment :
    • Treatment should be based on likely etiology, age and clinical status of the patient
    • Antibiotic treatment is usually not required in mild cases in preschool aged children as most cases are viral
Outpatient treatment
  • Age 1 - 3 months:
    • Erythromycin
    • Macrolide (azithromycin or clarithromycin)
  • Age 4 months -18 years:
    • Amoxicillin
    • Amoxicillin-clavulanate (2nd line)
    • If atypical organism suspected add:
      • Macrolide (azithromycin or clarithromycin) OR
      • Doxycycline (only if age>8 years)
Start IV antibiotic therapy for moderate to severely ill children who need admission:
    • Neonate:
      • Ampicillin and gentamicin +/- cefotaxime
      • Azithromycin or erythromycin for suspected C. trachomatis or B. pertussis pneumonia
      • Add vancomycin if MRSA a concerny
    • Age 1-3 months:
      • Erythromycin or azithromycin as 1st line agent + cefotaxime if febrile
      • Ampicillin if lobar pneumonia to cover for S.pneumoniae
    • Age 4 months - 18 years:
      • Ampicillin OR
      • Cefotaxime or Ceftriaxone as alternative or if not fully immunized
      • Vancomycin may be added for suspected or confirmed penicillin-resistant S. pneumoniae or MRSA
      • Macrolide may be added (i.e., azithromycin, clarithromycin or erythromycin) for suspected M. pneumoniae
Consult with local infectious disease service if poor response, unusual organisms, or in immunocompromised or special patient groups.

Medications indicated with specific doses

Penicillins

Cephalosporins

Glycopeptides

Macrolides

Aminoglycoside

Disposition

Admission criteria

  • Apnea
  • Dehydration and vomiting
  • Hypoxia or respiratory distress
  • Immunocompromised status
  • Infants aged <2 months with cough and/or difficult or rapid breathing
  • Infants aged <6 months with lobar pneumonia
  • Poor social support or family dynamics
  • Pleural effusion
  • Poor response to outpatient oral therapy
  • Toxic or septic appearance
Discharge criteria
  • Patients are usually discharged when there is no concern of hypoxia, respiratory distress, dehydration, vomiting, or noncompliance
  • The patient has to be able to maintain hydration and take the prescribed medication
  • There must be reliable family and social supports and appropriate precautions of indications to return for urgent or routine medical attention
  • Ability to attend follow up in 1-2 days

Follow-up

Monitoring

  • Pediatric patients treated for pneumonia, whether being discharged from the inpatient setting or to home from the outpatient setting should have initial follow up in 1-3 days
  • Children should be monitored following discharge until complete clinical recovery A follow up chest X-ray may be indicated post severe disease, prolonged resolution and/or on suspicion of development of complications
  • An anatomic irregularity, inhaled foreign object, or immunologic disorder should be suspected in case of persistent or recurrent pneumonia
  • Children should be monitored for growth and development, otitis media, reactive airway disease, and other complications

Complications

Airway injury

  • Atelectasis
  • Bronchopleural fistula
  • Chronic lung disease
  • Empyema
  • Hypoxia induced end organ injury
  • Lung abscess
  • Mechanical ventilation
  • Persistent newborn pulmonary hypertension
  • Pleural effusion
  • Pneumatocele
  • Pneumomediastinum
  • Pneumothorax
  • Sepsis-bacteremia

Miscellaneous

Prevention

  • Proper nutrition and exclusive breastfeeding during the first 6 months of life to build natural immunity in children
  • Reduction of indoor air pollution, maintenance of good hygiene in crowded dwellings and avoidance of infectious contacts are useful measures for prevention of pneumonia
  • Zinc supplementation in children with zinc deficiency has been known to reduce the incidence and prevalence of pediatric pneumonia
  • Prophylactic administration of co-trimoxazole (trimethoprim-sulfamethoxazole) reduces the risk of acquiring Pneumocystis jirovecii pneumonia in HIV-positive children
  • Vaccination
    • Pneumococcal vaccines
      • Conjugated pneumococcal vaccines can effectively reduce the risk of pneumonia in young children
      • Pneumococcal 7-valent conjugated vaccine (Prevnar or PCV7) for infants and young children
      • A new 13-valent conjugated vaccine (Prevnar 13 or PCV13) introduced in 2010 has replaced the PCV7 vaccine. A booster dose of PCV13 is recommended in all children previously vaccinated with PCV7
    • Influenza vaccine:
      • Immunization against influenza yearly is with an IM inactivated vaccine (for >6 months of age) or cold-adapted intranasal attenuated vaccine (for age >2yrs) is recommended for all children
      • Vaccination is most critical in high risk patients, such as those with cystic fibrosis, asthma, and bronchopulmonary dysplasia
    • H. influenzae type B (HIB) vaccine:
      • Conjugated HIB vaccine is recommended as a part of routine pediatric immunization regimen, and has drastically reduced the occurrence of pneumonia in

Prognosis

  • The prognosis of uncomplicated pediatric pneumonia is generally good, with significant recovery seen in 3 -5 days
  • Viral pneumonia usually resolves without treatment
  • Bacterial pneumonia tends to rapidly improve with administration of appropriate antimicrobials. The exception is staphylococcal pneumonia which can be severe and have a protracted course despite appropriate antibiotic therapy
  • The majority of patients with complicated pediatric pneumonia show complete recovery of lung function. Radiologic findings may take longer to resolve
  • One meta-analysis showed an overall risk of long term major respiratory sequelae from childhood pneumonia in non-hospitalized children of 5.5% , with the risk being up to three times higher in hospitalized children
  • Morbidity is significantly higher in neonates and children with underlying lung conditions
  • Patients with underlying lung conditions, congenital heart disease, and immunocompromise have a higher risk of mortality
    • Most deaths due to pediatric pneumonia occur in developing countries
    • Worldwide, lower respiratory tract infections are the 2nd leading cause of death in children <5 years of age

ICD9-CM

  • 486 Pneumonia, organism unspecified
  • 507.0 Pneumonitis due to inhalation of food or vomitus
  • 516.8 Other specified alveolar and parietoalveolar pneumonopathies

ICD-10CM

  • J18.9 Pneumonia, unspecified organism
  • J69.0 Pneumonitis due to inhalation of food and vomit
  • J84.09 Other alveolar and parietoalveolar conditions

References

  1. Rudan I, Boschi-Pinto C, Biloglav Z, et al. Epidemiology and etiology of childhood pneumonia. Bull World Health Organ. 2008;86(5):408-416. abstract
  2. Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. JAMA. Sep 15 2004;292(11):1333-1340. abstract
  3. Mishaan AM, Mason EO Jr, Martinez-Aguilar G, et al. Emergence of a predominant clone of community-acquired Staphylococcus aureus among children in Houston, Texas. Pediatr Infect Dis J. 2005;24(3):201-206. abstract
  4. Michelow IC, Olsen K, Lozano J, et al. Epidemiology and clinical characteristics of community-acquired pneumonia in hospitalized children. Pediatrics. 2004;113(4):701-707. abstract
  5. Tajima T, Nakayama E, Kondo Y, et al. Etiology and clinical study of community-acquired pneumonia in 157 hospitalized children. J Infect Chemother. 2006;12(6):372-379. abstract
  6. Tsolia MN, Psarras S, Bossios A, et al. Etiology of community-acquired pneumonia in hospitalized school-age children: evidence for high prevalence of viral infections. Clin Infect Dis. 2004;39(5):681-686. abstract
  7. Nascimento-Carvalho CM, Ribeiro CT, Cardoso MR, et al. The role of respiratory viral infections among children hospitalized for community-acquired pneumonia in a developing country. Pediatr Infect Dis J. 2008;27(10):939-941. abstract
  8. Ostapchuk M, Roberts DM, Haddy R. Community-acquired pneumonia in infants and children. Am Fam Physician. 2004;70(5):899-908. abstract
  9. Redd SC, Vreuls R, Metsing M, et al. Clinical signs of pneumonia in children attending a hospital outpatient department in Lesotho. Bull World Health Organ 1994;72(1):113-118. abstract
  10. Margolis P, Gadomski A. The rational clinical examination. Does this infant have pneumonia? JAMA 1998;279(4):308-313. abstract
  11. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44 Suppl 2:S27-72.
  12. Murphy CG, van de Pol AC, Harper MB, et al. Clinical predictors of occult pneumonia in the febrile child. Acad Emerg Med. 2007;14(3):243-249. abstract
  13. Muszynski JA, Knatz NL, Sargel CL, et al. Timing of correct parenteral antibiotic initiation and outcomes from severe bacterial community-acquired pneumonia in children. Pediatr Infect Dis J. 2011 Apr;30(4):295-301. abstract
  14. Willwerth BM, Harper MB, Greenes DS. Identifying hospitalized infants who have bronchiolitis and are at high risk for apnea. Ann Emerg Med. 2006 Oct;48(4):441-447. abstract
  15. Cincinnati Children's Hospital Medical Center. Evidence-based care guideline for community-acquired pneumonia in children 60 days through 17 years of age. http://www.cincinnatichildrens.org/assets/0/78/1067/2709/2777/2793/9199/1633ae60-cbd1-4fbd-bba4-cb687fbb1d42.pdf. Updated December 22, 2005. Last Accessed September 03, 2012.
  16. Chibuk TK, Cohen E, Robinson JL, et al. Paediatric complicated pneumonia: Diagnosis and management of empyema. Paediatr Child Health. 2011 Aug;16(7):425-429. abstract
  17. Lee GE, Lorch SA, Sheffler-Collins S, et al. National hospitalization trends for pediatric pneumonia and associated complications. Pediatrics. 2010 Aug;126(2):204-213. abstract
  18. Wexler ID, Knoll S, Picard E, et al. Clinical characteristics and outcome of complicated pneumococcal pneumonia in a pediatric population. Pediatr Pulmonol. 2006 Aug;41(8):726-734. abstract
  19. Lassi ZS, Haider BA, Bhutta ZA. Zinc supplementation for the prevention of pneumonia in children aged 2 months to 59 months. Cochrane Database Syst Rev. 2010;(12):CD005978. abstract
  20. World Health Organization. Pneumonia: Fact sheet. http://www.who.int/mediacentre/factsheets/fs331/en/index.html. Last accessed August 28, 2012.
  21. Darkes MJ, Plosker GL. Pneumococcal conjugate vaccine (Prevnar; PNCRM7): a review of its use in the prevention of Streptococcus pneumoniae infection. Paediatr Drugs. 2002;4(9):609-630. abstract
  22. Paradiso PR. Advances in pneumococcal disease prevention: 13-valent pneumococcal conjugate vaccine for infants and children. Clin Infect Dis. 2011 May;52(10):1241-1247. abstract
  23. Levine OS, Lagos R, Muñoz A, et al. Defining the burden of pneumonia in children preventable by vaccination against Haemophilus influenzae type b. Pediatr Infect Dis J. 1999 Dec;18(12):1060-1040. abstract
  24. Madhi SA, De Wals P, Grijalva CG, Grimwood K, et al. The burden of childhood pneumonia in the developed world: a review of the literature. Pediatr Infect Dis J. 2012 Oct 24. [Epub ahead of print] abstract
  25. Honkinen M, Lahti E, Österback R, Ruuskanen O, et al. Viruses and bacteria in sputum samples of children with community-acquired pneumonia. Clin Microbiol Infect. 2012 Mar;18(3):300-7 abstract
  26. Edmond K, Scott S, Korczak V, Ward C, et al. Long term sequelae from childhood pneumonia; systematic review and meta-analysis. PLoS One. 2012;7(2):e31239. doi: 10.1371/journal.pone.0031239 abstract